Company intelligence · Nasdaq: AMGN

Amgen: pipeline and clinical trials

Amgen is developing olpasiran, a small interfering RNA that lowers lipoprotein(a), in two large cardiovascular outcomes trials. Amgen sponsors about 104 active clinical trials, with obesity and cardiovascular disease prominent.

Legal name (SEC)AMGEN INC
ListingNasdaq: AMGN
HeadquartersThousand Oaks, California, United States
SEC filingsEDGAR (CIK 318154)
Focus areasCardiovascular disease, Obesity, Oncology, Inflammation

Key points

  • Amgen sponsors 104 active trials on ClinicalTrials.gov, 50 of them in Phase 3.
  • Olpasiran's OCEAN(a)-Outcomes trial (7,297 participants) has an estimated primary completion in March 2028, likely the next major Lp(a) outcomes readout.
  • A second olpasiran outcomes trial, OCEAN(a)-PreEvent (estimated 11,000 participants), is testing primary prevention.
  • Amgen's largest active Phase 3 trial is MARITIME-CV (12,800 participants), a cardiovascular outcomes study of its obesity drug maridebart cafraglutide.
  • Pelacarsen's 2026 Lp(a)HORIZON failure raises the stakes for Amgen's Lp(a) program.

Tracked drug profiles

Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.

Active clinical trials

ClinicalTrials.gov lists 104 active trials with Amgen as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Amgen".

By phase

Phase 127
Phase 1/24
Phase 213
Phase 350
Phase 47
Not applicable3

Most common conditions

  • Obesity (11)
  • Overweight (8)
  • Extensive Stage Small Cell Lung Cancer (4)
  • Small Cell Lung Cancer (4)
  • Prostate Cancer (3)
  • Cardiovascular Disease (3)
  • Neuromyelitis Optica Spectrum Disorder (3)
  • Thyroid Eye Disease (3)

Conditions as registered by the sponsor; one trial can list several.

Largest active Phase 3 trials

TrialEnrollmentPrimary completion
MARITIME-CV · NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
12,800Jun 30, 2028
NCT07136012
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
11,000Oct 20, 2031
NCT05581303
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
7,297Mar 31, 2028
MARITIME-HF · NCT07037459
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
5,056Jun 30, 2028
MARITIME-1 · NCT06858839
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
3,853Jan 21, 2027
NCT07684235
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
3,200Dec 26, 2027
MARITIME-T2D-3 · NCT07866066
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
1,300Sep 6, 2028
MARITIME-2 · NCT06858878
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
1,105Jan 21, 2027
NCT07684144
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
950Dec 26, 2027
NCT06747949
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
844Dec 11, 2029

See this sponsor’s trials on ClinicalTrials.gov

Two big cardiovascular bets

According to the registry, Amgen's largest active late-stage programs are in cardiometabolic disease:

  • Olpasiran for elevated lipoprotein(a), in OCEAN(a)-Outcomes and OCEAN(a)-PreEvent.
  • Maridebart cafraglutide, an obesity drug, in cardiovascular (MARITIME-CV) and heart failure (MARITIME-HF) trials. Spectral Genomics does not yet profile this drug.

Amgen also markets evolocumab (Repatha), an injectable PCSK9 antibody. That gives it established experience in large cardiovascular outcomes trials.

What to watch

  • OCEAN(a)-Outcomes, estimated primary completion March 2028 (registry). After Lp(a)HORIZON, this result will be read as a test of the Lp(a) hypothesis, not only of olpasiran.
  • Any amendments to the olpasiran trials in the registry.

Recent milestones

  1. Nov 6, 2022OCEAN(a)-DOSE Phase 2 results for olpasiran published. Peer-reviewed
  2. Dec 14, 2022OCEAN(a)-Outcomes begins. Registry
  3. Aug 22, 2025OCEAN(a)-PreEvent begins. Registry
  4. Sep 4, 2026Read-across: pelacarsen's Lp(a)HORIZON outcomes trial misses its primary endpoint. Company-reported

Sources

  1. SEC EDGAR: Amgen Inc. filings (CIK 318154).Regulator
  2. O'Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. New England Journal of Medicine. 2022;387(20):1855–1864.Peer-reviewed
  3. ClinicalTrials.gov. OCEAN(a)-Outcomes (NCT05581303).Registry
  4. ClinicalTrials.gov. MARITIME-CV (NCT07037433).Registry
  5. ClinicalTrials.gov: active trials with this lead sponsorRegistry

This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.